Pharmaceutical Research

, Volume 27, Issue 5, pp 933–942

Folate-PEG-CKK2-DTPA, A Potential Carrier for Lymph-Metastasized Tumor Targeting

Research Paper



A novel conjugate, Folate-PEG-CKK2-DTPA, was designed and prepared as a carrier for lymphatic metastasized tumor imaging diagnosis and targeting therapy.


Folate-PEG-CKK2-DTPA was synthesized and characterized by analysis High Performance Liquid Chromatography, Size Exclusive Chromatography and 1H-NMR. 99mTc-labeled conjugation was prepared, and in vivo quantitative biodistribution and SPECT imaging were studied after subcutaneously injected into the rats and rabbits, respectively. Cell uptake study was carried in a KB cell line using fluorescent methods. In vivo and ex vivo fluorescent imaging study was carried in tumor-bearing nude mouse to evaluate its targeting ability.


Folate-PEG-CKK2-DTPA was synthesized with high purity. Both in vivo biodistribution study and SPECT imaging study show the rapid direction and high distribution of the conjugation to the lymph nodes. The uptake of fluorescence-labeled Folate-PEG-CKK2-DTPA in human oral epidermis carcinoma cells was observed. In vivo and ex vivo fluorescent imaging study indicated it could accumulate in tumor region after vein tail injection in nude mouse.


All these findings suggested Folate-PEG-CKK2-DTPA as a novel and dependable carrier for tumor diagnosis and therapy, especially for lymph-metastasized tumors.


fluorescent imaging folate-PEG-CKK2-DTPA lymph targeting radio active tracing tumor targeting 



Bull Calf Serum






dimethyl sulfoxide


diethylenetriaminepentaacetic acid




1-Ethyl-3-(3-dimethyllaminopropyl) carbodiimide hydrochloride


Fetal bovine serum




Folate receptor




hydrogen fluoride




high-performance liquid chromatography


human oral epidermoid carcinoma


maleimide-polyethyl glycol-succinimidyl ester


Region of Interest


Single-Photon-Emission Computed Tomography


trifluoacetic acid


1H nuclear magnetic resonance


  1. 1.
    Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50:3–20.CrossRefPubMedGoogle Scholar
  2. 2.
    Hanahanand D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRefGoogle Scholar
  3. 3.
    Oussorenand C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev. 2001;50:143–56.CrossRefGoogle Scholar
  4. 4.
    Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev. 2002;54:235–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Torabi M, Aquino SL, Harisinghani MG. Current Concepts in Lymph Node Imaging. J Nucl Med. 2004;45:1509–18.PubMedGoogle Scholar
  6. 6.
    Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med. 2006;12:1213–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Koyama Y, Talanov VS, Bernardo M, Hama Y, Regino CA, Brechbiel MW, et al. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging. 2007;25:866–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Moghimiand SM, Bonnemain B. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv Drug Deliv Rev. 1999;37:295–312.CrossRefGoogle Scholar
  9. 9.
    Tanis PJ, Boom RPA, Koops HS, Faneyte IF, Peterse JL, Nieweg OE, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol. 2001;8:222–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Korst RJ, Ailawadi M, Lee JM, Lee S, Yamada R, Mahtabifard A, et al. Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic transgene. Hum Gene Ther. 2001;12:1639–49.CrossRefPubMedGoogle Scholar
  11. 11.
    Konno H, Tadakuma T, Kumai K, Takahashi T, Ishibiki K, Abe O, et al. The antitumor effects of adriamycin entrapped in liposomes on lymph node metastases. Jpn J Surg. 1990;20:424–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Khato J, Priester ER, Sieber SM. Enhanced lymph node uptake of melphalan following liposomal entrapment and effects on lymph node metastasis in rats. Cancer Treat Rep. 1982;66:517–27.PubMedGoogle Scholar
  13. 13.
    Kaledin VI, Matienko NA, Nikolin VP, Gruntenko YV, Budker VG. Intralymphatic administration of liposome-encapsulated drugs to mice: possibility for suppression of the growth of tumor metastases in the lymph nodes. J Natl Cancer Inst. 1981;66:881–7.PubMedGoogle Scholar
  14. 14.
    Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res. 2008;147:247–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Oussoren C, Eling WMC, Crommelin DJA, Storm G, Zuidema J. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochim Biophys Acta, Biomembranes. 1998;1369:159–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Sudimackand J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147–62.CrossRefGoogle Scholar
  17. 17.
    Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, et al. Immunohistochemical expression of folate receptor [alpha] in colorectal carcinoma: patterns and biological significance. Human Pathol. 2008;39:498–505.CrossRefGoogle Scholar
  18. 18.
    Nabil FS, Xu W, Susan M, Mourad T, Kwangjae C, Shuming N, et al. Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head & Neck. 2009;31:475–81.CrossRefGoogle Scholar
  19. 19.
    Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt. 2003;8:636–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Green MA. Indium-111-DTPA-Folate as a potential folate receptor-targeted radiopharmaceutical. J Nucl Med. 1998;39:1579–85.PubMedGoogle Scholar
  21. 21.
    Fisher RE, Siegel BA, Edell SL, Oyesiku NM, Morgenstern DE, Messmann RA, et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. jnumed.107.049478 (2008).Google Scholar
  22. 22.
    Muller C, Forrer F, Schibli R, Krenning EP, de Jong M. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-Radiofolate. J Nucl Med. 2008;49:310–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Moghimiand M, Moein Moghimi S. Lymphatic targeting of immuno-PEG-liposomes: evaluation of antibody-coupling procedures on lymph node macrophage uptake. J Drug Target. 2008;16:586–90.CrossRefGoogle Scholar
  24. 24.
    Moghimi SM. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials. 2006;27:136–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev. 2008;60:1347–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Kaiser RLCE, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. 1970;34:595–598.Google Scholar
  27. 27.
    Liu M, Xu W, Xu L-J, Zhong G-R, Chen S-L, Lu W-Y. Synthesis and biological evaluation of diethylenetriamine pentaacetic acid-polyethylene glycol-folate: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem. 2005;16:1126–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Mathias CJ, Hubers D, Low PS, Green MA. Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem. 2000;11:253–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Bettio A, Honer M, Muller C, Bruhlmeier M, Muller U, Schibli R, et al. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med. 2006;47:1153–60.PubMedGoogle Scholar
  30. 30.
    Muller C, Hohn A, Schubiger PA, Schibli R. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur J Nucl Med Mol Imaging. 2006;33:1007–16.CrossRefPubMedGoogle Scholar
  31. 31.
    Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: effect of alternative conjugation chemistry. J Drug Target. 1999;7:157–69.CrossRefPubMedGoogle Scholar
  32. 32.
    Maisano F, Gozzini L, De Haen C. Coupling of DTPA to proteins: a critical analysis of the cyclic dianhydride method in the case of insulin modification. Bioconjug Chem. 2002;3:212–7.CrossRefGoogle Scholar
  33. 33.
    McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005;2:89–96.CrossRefGoogle Scholar
  34. 34.
    Harrell MI, Iritani BM, Ruddell A. Lymph node mapping in the mouse. J Immunol Methods. 2008;332:170–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev. 1995;17:129–48.CrossRefGoogle Scholar
  36. 36.
    Illum L, Hunneyball IM, Davis SS. The effect of hydrophilic coatings on the uptake of colloidal particles by the liver and by peritoneal-macrophages. Int J Pharm. 1986;29:53–65.CrossRefGoogle Scholar
  37. 37.
    Birn H, Nielsen S, Christensen EI. Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule. Am J Physiol Renal Physiol. 1997;272:F70–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Bing Gu
    • 1
  • Cao Xie
    • 1
  • Jianhua Zhu
    • 1
  • Wei He
    • 2
  • Weiyue Lu
    • 1
  1. 1.School of PharmacyFudan UniversityShanghaiChina
  2. 2.Department of Nuclear MedicineHuadong HospitalShanghaiChina

Personalised recommendations